The development of DDR inhibitors, particularly targeting poly(ADP-ribose) polymerase 1 (PARP1), offers new strategies for enhancing the effectiveness of traditional cancer treatments and improving patient outcomes. This evidence concerns the gene PARP1 and cancer.